
Kevin Gorman, Neurocrine CEO
Bouncing back from a PhII flop in schizophrenia, Neurocrine steers into the busy M4/M1 pathway with a $100M cash deal
Eight months after Neurocrine $NBIX chronicled a flop for a mid-stage schizophrenia drug, the biotech is headed right back into Phase II armed with a new drug candidate from Sosei Heptares.
Neurocrine outlined a deal that provides Sosei Heptares $100 million upfront, R&D expenses and a motherlode of milestones worth up to $2.6 billion if successful. That starting figure closely resembles what the biotech paid Takeda to land 3 programs, including the schizophrenia drug TAK-831, which failed to measure up in the clinic.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters